Oxytocin Research: The Cyclic Nonapeptide and What Studies Have Investigated

What is oxytocin?

What is oxytocin? As a molecule, it is a cyclic nonapeptide — a chain of nine amino acids, with the sequence Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂. Two features define its structure: a disulfide bridge links the two cysteine residues (positions 1 and 6) to close a 20-membered ring, and the C-terminal glycine is amidated. The ring, in the shorthand of peptide chemistry, is the “cyclic” part; the residues past the second cysteine (Pro-Leu-Gly-NH₂) form an acyclic “tail.” This is a neutral molecular definition — a description of a chemical structure — and the sections below cover how that structure was determined and what receptor and signalling research has examined, not any effect in an organism.

Discovery and origin in the literature

Naming and early history

Oxytocin takes its name from the Greek oxys and tokos (“quick birth”), reflecting the early-twentieth-century observation, associated with Henry Dale, that a posterior-pituitary extract acted on uterine smooth muscle in tissue preparations. That is historical context for the molecule’s name; it is reported here as the origin of the terminology, not as a property of the research material.

Sequencing and chemical synthesis (1953–1954)

The molecule’s modern identity rests on the work of Vincent du Vigneaud’s laboratory. In 1953 du Vigneaud, Ressler and Trippett published the amino-acid sequence and a proposed structure (J Biol Chem, PMID 13129273), and in 1954 du Vigneaud and colleagues reported the total chemical synthesis of oxytocin (J Am Chem Soc). The achievement was historically significant because it was among the first chemical syntheses of a polypeptide hormone, and du Vigneaud received the 1955 Nobel Prize in Chemistry “for his work on biochemically important sulphur compounds, especially for the first synthesis of a polypeptide hormone.” The sulphur reference is apt: the disulfide bridge between the two cysteines is exactly one of those sulphur-containing features. Today the research material is manufactured to that defined sequence rather than extracted from tissue.

Reference data

The molecule facts below are drawn from the public chemical record (PubChem CID 439302) and standard catalogue data. They describe identity and physical form only.

These are catalogue and coordinate-chemistry facts — sequence, mass, salt-free identity and handling form. No reconstitution procedure, quantity or route is given or implied; the material is characterised as a dry powder, which is its stable state.

Mechanisms researchers have examined

The oxytocin mechanism literature is, at the molecular level, receptor-signalling literature. Each point below is framed as what studies characterise, not as an effect in a reader:

• The oxytocin receptor (OXTR) — a class A (rhodopsin-family) G-protein-coupled receptor. Gimpl & Fahrenholz (2001, Physiol Rev, PMID 11274341) reviewed its structure, ligand binding and regulation.
• Gq/11 – phospholipase C signalling — receptor activation is described as coupling primarily to Gq/11, stimulating phospholipase C, generating inositol trisphosphate (IP₃) and mobilising intracellular Ca²⁺ in the systems studied.
• Relationship to vasopressin — oxytocin and arginine-vasopressin are near-identical nonapeptides differing at two residue positions, and act at a family of closely related receptors (OXTR; V1a/V1b/V2). The molecular cross-talk between these ligands and receptors is a recurring subject in the literature (Stoop, 2012, Neuron, PMID 23040812).
• Intracellular signalling to downstream pathways — Jurek & Neumann (2018, Physiol Rev) reviewed the receptor’s intracellular signalling cascades as characterised in cellular and animal-model research.

Every bullet names a receptor or a signalling pathway that research has characterised in model systems. None is an outcome, and none describes anything a reader would experience.

Research areas in the literature

Beyond the core receptor pharmacology, oxytocin appears across a molecular-neuroscience literature that studies where the receptor is expressed and how the peptide signals in the nervous system. Described strictly as what investigators examined:

• Receptor distribution and neuromodulation — Stoop (2012, Neuron) surveyed how oxytocin and vasopressin act as neuromodulators, examining receptor localisation and electrophysiological effects in neural circuits in animal models.
• Signalling-to-cellular-response research — Jurek & Neumann (2018) traced the pathway from OXTR activation through intracellular second messengers, a mechanistic review of the receptor system.
• Comparative neuropeptide research — Meyer-Lindenberg et al. (2011, Nat Rev Neurosci, PMID 21852800) reviewed oxytocin and vasopressin as a class of neuropeptides studied in translational neuroscience; it is cited here as a survey of a research field, not as evidence of any effect.

These are records of what the literature has investigated at the receptor and circuit level. This page draws no conclusion about function in humans and offers nothing a reader should expect from the compound.

Research models and evidence status

To be explicit about where this material sits: oxytocin is one of the most-studied peptides in biochemistry, but the work relevant to a research reference like this one is molecular and receptor in nature — synthesis and structure, OXTR pharmacology, and cell- and animal-model signalling studies. What is not established, and is deliberately not claimed here, is any effect of the supplied research material in a person: this page describes chemistry and receptor biology, makes no efficacy, therapeutic, behavioural or other use claim of any kind, and the product is not for human or veterinary use. A study that mapped a receptor or measured a calcium signal is a record of what was investigated in a controlled setting, not an outcome offered to the reader.

How to verify this compound yourself

For a small cyclic peptide, identity and purity are established by two orthogonal analytical methods, and both appear on a per-batch Certificate of Analysis:

• HPLC purity — reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and reports purity as a percentage of the chromatogram.
• Mass-spec identity — mass spectrometry confirms the measured mass against the expected molecular weight (≈ 1007 Da), which for oxytocin also checks that the disulfide ring is intact rather than reduced.
• Endotoxin / sterility — where tested, these are separate quality attributes of the material reported in EU/mL or as a sterility result, independent of chemical purity.

See how to read a COA for what each line on the certificate means, and how to verify peptide purity for how HPLC and mass spec fit together. The exact batch received can be checked on the self-serve verify tool.

Research-grade sourcing and verification

For laboratory research use only, oxytocin is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation, verifiable at the lot level. Because a chemistry summary is only as meaningful as the identity of the material behind it, that documentation — not assumption — is what defines a reproducible research peptide. This is sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. du Vigneaud V, Ressler C, Trippett S. “The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin.” J Biol Chem. 1953;205(2):949–957. PMID 13129273. pubmed.ncbi.nlm.nih.gov/13129273.
2. du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG. “The Synthesis of Oxytocin.” J Am Chem Soc. 1954;76(12):3115–3121. doi.org/10.1021/ja01641a004.
3. Gimpl G, Fahrenholz F. “The oxytocin receptor system: structure, function, and regulation.” Physiol Rev. 2001;81(2):629–683. PMID 11274341. pubmed.ncbi.nlm.nih.gov/11274341.
4. Jurek B, Neumann ID. “The Oxytocin Receptor: From Intracellular Signaling to Behavior.” Physiol Rev. 2018;98(3):1805–1908. PMID 29897293. pubmed.ncbi.nlm.nih.gov/29897293.
5. Stoop R. “Neuromodulation by oxytocin and vasopressin.” Neuron. 2012;76(1):142–159. PMID 23040812. pubmed.ncbi.nlm.nih.gov/23040812.
6. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. “Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine.” Nat Rev Neurosci. 2011;12(9):524–538. PMID 21852800. pubmed.ncbi.nlm.nih.gov/21852800.
7. National Center for Biotechnology Information. “PubChem Compound Summary for CID 439302, Oxytocin.” pubchem.ncbi.nlm.nih.gov/compound/439302 (formula, mass, CAS 50-56-6).